The last year or so has been a rollercoaster ride for the global Invitro Diagnostic (IVD) market. In early 2020, business came to an abrupt halt as hospitals and clinics closed or reduced all non-essential treatments. However, the demand for SARS-CoV-2 testing rapidly changed the sector’s dynamics and, globally, we’ve seen increasing interest – especially in molecular diagnostic (MDx) technologies.